<div id="readability-page-1"><div>Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery.In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks:<ul><li>12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight.</li><li>9 mg dose: average weight loss of 64.4 pounds, or 25.9%.</li><li>4 mg dose: average weight loss of 47.2 pounds, or 19%</li></ul>Ahead of the results, RBC Capital Markets analyst Trung Huynh said the key success range would be 28% to 30% weight loss.Lilly's 12 mg dose appears to have cleared the low end of Huynh's bar, with patients losing an average of 28.3% of their body weight over 80 weeks.&#34;We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine,&#34; Kenneth Custer, president of Lilly Cardiometabolic Health, told Bloomberg in an interview.Custer added, &#34;I think we can definitively check the box&#34; based on the data that &#34;retatrutide moves the goalpost on max efficacy.&#34;Retatrutide is a first-in-class triple hormone receptor agonisttargeting GIP, GLP-1, and glucagon, positioning it as potentially superior to current weight-loss drugs such as Lilly's Zepbound, Novo Nordisk's Wegovy, and copycat GLP-1s.Lilly noted some downsides to taking the drug in the trial:<blockquote>Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide</blockquote>In markets, Lilly shares rose about 1% in premarket trading in New York, while shares of the Wegovy competitor, Novo Nordisk, traded in Copenhagen, fell slightly.<img width="500" height="277" src="https://imageproxy.pbkrs.com/https://files.zhedge.com/cdn-cgi/image/width=1920,quality=75,format=auto/https://assets.zerohedge.com/s3fs-public/inline-images/Snag_96be8ff5.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://files.zhedge.com/cdn-cgi/image/width=1920,quality=75,format=auto/https://assets.zerohedge.com/s3fs-public/inline-images/Snag_96be8ff5.png"/>Latest in the GLP-1 space:<ul><li>HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook</li></ul>The key question is whether bariatric surgery begins to lose favor among patients as next-generation obesity medications replicate, or come close to replicating, surgery-level weight loss without an invasive procedure.</div></div>

禮來

2 倍做多 LLY ETF - Direxion

2 倍做多 LLY ETF - Defiance

2 倍做多 NVO ETF - Defiance

禮來的下一代肥胖藥物 retatrutide 在第三階段臨牀試驗中顯示出良好的結果，達到的減重效果可與減肥手術相媲美。在 TRIUMPH-1 試驗中，參與者在 80 周內以 12 毫克劑量平均減重 28.3%。儘管有一些輕微的副作用，但該藥物的療效使其在減重市場中成為強有力的競爭者。禮來股票在盤前交易中上漲了 1%，而競爭對手諾和諾德的股票則小幅下跌

禮來的下一代減肥藥在試驗中取得了接近減肥手術的效果